Aktuelle smitsomme sygdomme
Søgeord (hepatitis b) valgt.
6 emner vises.
Medscape Infectious Diseases, 31.08.2024
Tilføjet 31.08.2024
The rules about whom to screen and vaccinate for hepatitis B are now more clinician-friendly. The Curbsiders
Læs mereJulien Beauté and Francesco Innocenti
Eurosurveillance latest updates, 17.08.2024
Tilføjet 17.08.2024
Background There are differences between males and females for most diseases both for exposure and course of illness, including outcome. These differences can be related to biological sex or gender i.e. socio-cultural factors that may impact exposure and healthcare access. Aim We aimed to quantify differences between males and females in infectious disease notifications in Europe and identify countries with these differences significantly different from the European Union and European Economic Area (EU/EEA) average. Methods Notifiable infectious disease surveillance data are reported by EU/EEA countries to ECDC. We retrieved surveillance data for 2012−2021. Using a cut-off median of annual disability-adjusted life years above 1 per 100,000 population, we included 16 infectious diseases. We calculated median male proportion and interquartile range by disease, year, country and age group and used boxplots to identify outliers. Results For campylobacteriosis, acute hepatitis B, Legionnaires’ disease, malaria and HIV and AIDS, all countries had male proportion above 50%. Most countries had a male proportion below 50% for pertussis (25/28 countries), STEC infection (21/28 countries) and Chlamydia trachomatis infection (16/24 countries). Chlamydia trachomatis infection and listeriosis showed the greatest dispersion of male proportion across age groups. Most outliers were countries reporting few cases. Conclusion We observed important differences in male proportion across infectious disease notifications in EU/EEA countries. For some diseases with high male proportions in all countries, such as HIV and hepatitis B, behaviours play a role in disease transmission. Screening offered to specific populations may explain differences across countries for example for C. trachomatis infection.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 2.08.2024
Tilføjet 2.08.2024
This report describes progress toward eliminating hepatitis B and C in the country of Georgia.
Læs mereMedscape Infectious Diseases, 29.07.2024
Tilføjet 29.07.2024
This requires sensitivity to stigmas and awareness of hepatitis B and C prevalence in local communities. Medscape Medical News
Læs mereMorbidity and Mortality Weekly Report (MMWR), 25.07.2024
Tilføjet 25.07.2024
Medscape Infectious Diseases, 15.05.2024
Tilføjet 15.05.2024
The U.S. drug regulator has declined to approve expanded use of Dynavax Technologies\' hepatitis B vaccine in a section of patients, citing insufficient data over destruction... Reuters Health Information
Læs mere